company background image
KNE

Kane Biotech TSXV:KNE Stock Report

Last Price

CA$0.12

Market Cap

CA$15.0m

7D

20.0%

1Y

-11.1%

Updated

06 Feb, 2023

Data

Company Financials

KNE Stock Overview

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally.

KNE fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

New

Notes are coming soon

Kane Biotech Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kane Biotech
Historical stock prices
Current Share PriceCA$0.12
52 Week HighCA$0.14
52 Week LowCA$0.075
Beta0.14
1 Month Change20.00%
3 Month Change33.33%
1 Year Change-11.11%
3 Year Change-36.84%
5 Year Change33.33%
Change since IPO-93.14%

Recent News & Updates

Recent updates

Here's Why Kane Biotech (CVE:KNE) Can Afford Some Debt

Nov 05
Here's Why Kane Biotech (CVE:KNE) Can Afford Some Debt

Is Kane Biotech (CVE:KNE) A Risky Investment?

Jul 14
Is Kane Biotech (CVE:KNE) A Risky Investment?

Is Kane Biotech (CVE:KNE) A Risky Investment?

Mar 27
Is Kane Biotech (CVE:KNE) A Risky Investment?

Shareholder Returns

KNECA BiotechsCA Market
7D20.0%-0.5%-0.05%
1Y-11.1%-11.1%-3.3%

Return vs Industry: KNE matched the Canadian Biotechs industry which returned -11.1% over the past year.

Return vs Market: KNE underperformed the Canadian Market which returned -3.3% over the past year.

Price Volatility

Is KNE's price volatile compared to industry and market?
KNE volatility
KNE Average Weekly Movement13.4%
Biotechs Industry Average Movement12.0%
Market Average Movement9.9%
10% most volatile stocks in CA Market19.0%
10% least volatile stocks in CA Market3.9%

Stable Share Price: KNE is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: KNE's weekly volatility (13%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001n/aMarc Edwardshttps://kanebiotech.com

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; animal and human wound care solutions under the DispersinB name; shampoos for dogs, cats, and horses under the Alosera name; and medical device coatings under the Aledex name. It also offers scalp care products under the DermaKB brand name, wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, and DermaKB Biofilm brand names.

Kane Biotech Inc. Fundamentals Summary

How do Kane Biotech's earnings and revenue compare to its market cap?
KNE fundamental statistics
Market CapCA$14.98m
Earnings (TTM)-CA$4.29m
Revenue (TTM)CA$2.39m

6.3x

P/S Ratio

-3.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KNE income statement (TTM)
RevenueCA$2.39m
Cost of RevenueCA$1.11m
Gross ProfitCA$1.28m
Other ExpensesCA$5.57m
Earnings-CA$4.29m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.034
Gross Margin53.59%
Net Profit Margin-179.57%
Debt/Equity Ratio-169.5%

How did KNE perform over the long term?

See historical performance and comparison